Cargando…

Involvement of toll-like receptor 9 polymorphism in cervical cancer development

The role played by the polymorphism located in Toll-like Receptor 9 (TLR9) as a risk factor of cervical cancer remains elusive. Therefore, we studied the association of the TLR9 −1486 T/C (rs187084) and C2848T (rs352140) polymorphisms with cervical cancer. The TLR9 −1486 T/C and C2848T polymorphism...

Descripción completa

Detalles Bibliográficos
Autores principales: Roszak, Andrzej, Lianeri, Margarita, Sowińska, Anna, Jagodziński, Pawel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383973/
https://www.ncbi.nlm.nih.gov/pubmed/22714906
http://dx.doi.org/10.1007/s11033-012-1695-8
_version_ 1782236659829440512
author Roszak, Andrzej
Lianeri, Margarita
Sowińska, Anna
Jagodziński, Pawel P.
author_facet Roszak, Andrzej
Lianeri, Margarita
Sowińska, Anna
Jagodziński, Pawel P.
author_sort Roszak, Andrzej
collection PubMed
description The role played by the polymorphism located in Toll-like Receptor 9 (TLR9) as a risk factor of cervical cancer remains elusive. Therefore, we studied the association of the TLR9 −1486 T/C (rs187084) and C2848T (rs352140) polymorphisms with cervical cancer. The TLR9 −1486 T/C and C2848T polymorphism was genotyped in 426 patients and 460 unrelated healthy females from the Polish population. Logistic regression analysis adjusting for age, pregnancy, oral contraceptive use, tobacco smoking, and menopausal status showed that both the TLR9 −1486 T/C and C2848T polymorphisms could be a genetic risk factor for cervical cancer. For the TLR9 −1486 T/C polymorphism, the adjusted OR for patients with the C/T genotype versus T/T genotype was 1.371 (95 % CI 1.021–1.842, p = 0.0361), the adjusted OR for the C/C genotype vs the T/T genotype was 1.300 (95 % CI 1.016–1.507, p = 0.0096), and the adjusted OR for the C/T or C/C genotype vs the T/T genotype was 1.448 (95 % CI 1.099–1.908, p = 0.0083). For the C2848T polymorphism, the adjusted OR for patients with the C/T genotype vs C/C genotype was 1.443 (95 % CI 1.019–2.043, p = 0.0380), the adjusted OR for the T/T genotype vs the C/C genotype was 1.237 (95 % CI 1.016–1.507, p = 0.0328), and the adjusted OR for the T/C or T/T genotype vs the C/C genotype was 1.345 (95 % CI 0.976–1.855, p = 0.0700). Our studies suggest that the TLR9 −1486 T/C and C2848T polymorphisms may be a genetic risk factor for cervical cancer.
format Online
Article
Text
id pubmed-3383973
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-33839732012-07-05 Involvement of toll-like receptor 9 polymorphism in cervical cancer development Roszak, Andrzej Lianeri, Margarita Sowińska, Anna Jagodziński, Pawel P. Mol Biol Rep Article The role played by the polymorphism located in Toll-like Receptor 9 (TLR9) as a risk factor of cervical cancer remains elusive. Therefore, we studied the association of the TLR9 −1486 T/C (rs187084) and C2848T (rs352140) polymorphisms with cervical cancer. The TLR9 −1486 T/C and C2848T polymorphism was genotyped in 426 patients and 460 unrelated healthy females from the Polish population. Logistic regression analysis adjusting for age, pregnancy, oral contraceptive use, tobacco smoking, and menopausal status showed that both the TLR9 −1486 T/C and C2848T polymorphisms could be a genetic risk factor for cervical cancer. For the TLR9 −1486 T/C polymorphism, the adjusted OR for patients with the C/T genotype versus T/T genotype was 1.371 (95 % CI 1.021–1.842, p = 0.0361), the adjusted OR for the C/C genotype vs the T/T genotype was 1.300 (95 % CI 1.016–1.507, p = 0.0096), and the adjusted OR for the C/T or C/C genotype vs the T/T genotype was 1.448 (95 % CI 1.099–1.908, p = 0.0083). For the C2848T polymorphism, the adjusted OR for patients with the C/T genotype vs C/C genotype was 1.443 (95 % CI 1.019–2.043, p = 0.0380), the adjusted OR for the T/T genotype vs the C/C genotype was 1.237 (95 % CI 1.016–1.507, p = 0.0328), and the adjusted OR for the T/C or T/T genotype vs the C/C genotype was 1.345 (95 % CI 0.976–1.855, p = 0.0700). Our studies suggest that the TLR9 −1486 T/C and C2848T polymorphisms may be a genetic risk factor for cervical cancer. Springer Netherlands 2012-06-20 2012 /pmc/articles/PMC3383973/ /pubmed/22714906 http://dx.doi.org/10.1007/s11033-012-1695-8 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Article
Roszak, Andrzej
Lianeri, Margarita
Sowińska, Anna
Jagodziński, Pawel P.
Involvement of toll-like receptor 9 polymorphism in cervical cancer development
title Involvement of toll-like receptor 9 polymorphism in cervical cancer development
title_full Involvement of toll-like receptor 9 polymorphism in cervical cancer development
title_fullStr Involvement of toll-like receptor 9 polymorphism in cervical cancer development
title_full_unstemmed Involvement of toll-like receptor 9 polymorphism in cervical cancer development
title_short Involvement of toll-like receptor 9 polymorphism in cervical cancer development
title_sort involvement of toll-like receptor 9 polymorphism in cervical cancer development
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383973/
https://www.ncbi.nlm.nih.gov/pubmed/22714906
http://dx.doi.org/10.1007/s11033-012-1695-8
work_keys_str_mv AT roszakandrzej involvementoftolllikereceptor9polymorphismincervicalcancerdevelopment
AT lianerimargarita involvementoftolllikereceptor9polymorphismincervicalcancerdevelopment
AT sowinskaanna involvementoftolllikereceptor9polymorphismincervicalcancerdevelopment
AT jagodzinskipawelp involvementoftolllikereceptor9polymorphismincervicalcancerdevelopment